{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02654132\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-22T14:50:57.040Z","note":"Automated from the 19 newest of 22 indexed sources (Aug 2018 – Apr 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":19,"text":"- Whether elotuzumab-pomalidomide-dexamethasone retains a role after daratumumab or other anti-CD38 exposure or refractoriness\n- How to interpret the overall survival analysis of elotuzumab plus pomalidomide-dexamethasone\n- Whether pomalidomide-dexamethasone remains an appropriate control arm, and how it performed versus other trials\n- Whether elotuzumab-pomalidomide-dexamethasone can be compared across trials with daratumumab- or isatuximab-pomalidomide-dexamethasone","kind":"questions"},"drugs_tested":[["elotuzumab"]],"indication":"relapsed and refractory multiple myeloma","name":"ELOQUENT-3","nct_id":"NCT02654132","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eloquent-3-nct02654132. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Biological:Elotuzumab (BMS-901608; HuLuc63)\n\n* Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)\n* Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)\n\nDrug: Pomalidomide\n\n•Capsules,Oral,4 mg,once daily, on Days 1-21\n\nOther Name: Pomalyst\n\nDrug: Dexamethasone\n\n* Subjects ≤ 75 years old:\n\n  •Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1\\&2) Day 1(Cycle 3 and Beyond)\n\n  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\\&2) Day 1(Cycle 3 and Beyond)\n\n  •Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)\n* Subjects \\> 75 years old:\n\n  •Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1\\&2) Day 1(Cycle 3 and Beyond)\n\n  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\\&2) Day 1(Cycle 3 and Beyond)\n\n  •Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)\n\nOther Names:\n\nDecadron,Dexamethasone ,Intensol,Dexpak,Taperpak","label":"Elotuzumab Arm","type":"EXPERIMENTAL"},{"description":"Drug: Pomalidomide\n\n• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst\n\nDrug: Dexamethasone\n\nSubjects ≤ 75 years old:\n\n• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22\n\nSubjects \\> 75 years old:\n\n• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,\n\nOther Names:\n\n* Decadron\n* Dexamethasone Intensol\n* Dexpak\n* Taperpak","label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":["Celgene","AbbVie"],"completion_date":{"date":"2021-10-21","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":117,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Elotuzumab","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":["Pomalyst"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Decadron, Dexamethasone, Intensol, Dexpak, Taperpak"],"type":"DRUG"}],"last_update":"2022-11-01","lead_sponsor":"Bristol-Myers Squibb","official_title":"An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-01-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization to date of progression or death (up to approximately 21 months)"}],"references":[{"citation":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12.","pmid":"35960908","type":"DERIVED"},{"citation":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.","pmid":"30403938","type":"DERIVED"}],"start_date":{"date":"2016-03-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)","url":"https://clinicaltrials.gov/study/NCT02654132"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eloquent-3-nct02654132"}